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Chiara Bonini,1 Malcolm K. Brenner,2 Helen E. Heslop,2 Richard A. Morgan3Adoptively transferred T cells have shown activity in treating viral infections after hemopoietic transplanta-
tion and anti-tumor activity against some malignancies such as melanoma and lymphoma. Current research
focuses on defining the optimum type of cell for transfer to improve persistence and genetically modifying
infused T cells to augment function, overcome tumor evasion strategies and allow ablation should adverse
effects occur.
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Adoptive transfer of T lymphocytes has proved
clinically effective after allogeneic hemopoietic stem
cell transplantation (HSCT) with unmanipulated do-
nor lymphocyte infusions (DLI) having activity in
a number of relapsed hematologic malignancies [1].
Ex vivo expanded, donor-derived, cytotoxic-specific
T lymphocytes (CTLs) are also highly effective in pre-
venting or treating viral infections and Epstein-Barr
virus (EBV) lymphomas developing posttransplant
[2-5] and have also shown antileukemia activity when
directed at minor antigens [6]. In the nontransplant
setting T cell therapies have had activity in a number
of cancers including melanoma and lymphoma [7,8].
Nevertheless, T cell immunotherapy faces a number
of challenges. For example, many tumors express
only weak antigens and may present them poorly and
have also evolved a number of immune evasion
strategies to avoid a transferred immune response
[9,10]. Gene transfer to infused T cells offers the
possibility of arming the T cell with additional
specificities to target tumor antigens or overcome
tumor evasion mechanisms and also of tra nsferring1Experimental Hematology Unit, Research Division of
erative Medicine, Gene Therapy and Stem Cells, Hema-
and BMT Unit, Department of Oncology, San Raffaele
tific Institute, Milano, Italy; 2Center for Cell and Gene
py, Baylor College of Medicine, The Methodist Hospital
exas Children’s Hospital, Houston, Texas; and 3Surgery
h, National Cancer Institute, Bethesda, Maryland.
isclosure: See Acknowledgments on page S19.
dence and reprint requests: Helen E.Heslop,MD,Center
ll andGeneTherapy, 1102 Bates St, Suite 1630,Houston,
7030 (e-mail: hheslop@bcm.edu).
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2010.09.019a safety switch to infused cells so they may be ablated
if adverse events occur.What Is the Optimal T Cell to Target?
An advantage of T cell–based immunotherapy com-
pared to conventional chemotherapy, small molecules,
and monoclonal antibodies is persistence because of
continual generation of antigen-specific effector and
memory T cells. In the presence of chronic infections
or cancer, this hallmark allows both responses to patho-
gens and patrolling for recurrence and minimal residual
disease. Nevertheless, persistence of genetically modi-
fied lymphocytes has been variable and often suboptimal
in clinical trials. This variability may be a result of
differences in the composition of infused cells, with
some studies infusing a mixture of CD41 and CD81
cells, and other pure populations of CD81 cytotoxic
cells [5,11]. In addition, T cells may differ in their
expansion potential, homing, and persistence, based
on their differentiation status. When T lymphocytes
encounter antigen they undergo a developmental
program from na€ıve (TNA), to central memory (TCM)
and effector memory (TEM) cells. Gene-modified
lymphocytes currently infused to patients are usually
generated starting from unselected circulating T cells
and will thus contain an unpredictable mixture of cellu-
lar subsets. Investigators are now trying to identify the
optimal T cell target for gene transfer. In a primate
model of cytomegalovirus (CMV) infection Berger
et al. [12] reported that genetically modified lympho-
cytes derived from TCM cells persist longer than gene-
modified effectors derived from TEM cells. Conversely,
Hinrichs et al. [13] reported in a murine model, that
gene-modified lymphocytes obtained from TNA cells
are superior to those obtained from TCM cells. These
results underline the difficulty in identifying the optimal
T cell subset to be geneticallymodified for every clinical
condition.S15
S16 Biol Blood Marrow Transplant 17:S15-S20, 2011C. Bonini et al.Independently from the cell of origin, it is impor-
tant to note that culture conditions used during the
gene modification procedure may affect the subse-
quent in vivo properties of T cells. Gene transfer is
usually achieved after T cell activation and culture in
the presence of high doses of IL-2. These culture
conditions induce T cell differentiation toward a late
effector state. Costimulation and culture in the pres-
ence of IL-7 and/or IL-15 promote the expansion of
gene modified lymphocytes with an early differentia-
tion phenotype and may allow greater expansion and
prolonged in vivo persistence [14]. The beneficial
role of homeostatic cytokines for T cell therapy might
be further exploited through gene transfer. Hoyos
et al. [15] recently compared the properties of T cells
genetically modified to express a chimeric antigen re-
ceptor directed to CD19 (CAR.19) alone with cells
modified to both express CAR.19 and the cytokine
IL15. Their results showed that the expansion of
IL15-producing cells was greater in vivo with corre-
spondingly enhanced antitumor activity.Lymphodepletion
The importance of lymphodepletion in adoptive
cell therapy (ACT) was first demonstrated by the
transfer of tumor-sensitized lymphocytes in recipient
mice made T cell–deficient by thymectomy and irradi-
ation [16]. Similarly, CD81 T cells isolated from
tumor-draining lymph nodes of tumor-bearing mice
actively proliferated and rejected the pulmonary me-
tastases only after total-body irradiation (TBI) [17].
Most recently, the role of lymphodepletion has been
extensively studied using a transgenic mousemodel ex-
pressing the pmel-1T cell receptor (TCR) recognizing
the murine gp100 melanoma-associated antigen [18].
Restifo and colleagues [19] have shown a pronounced
effect of lymphodepletion on the effectiveness of
ACT in this model. Several mechanisms likely contrib-
ute to the enhancing effect of lymphodepletion on
ACT. Postulated mechanisms include: (1) homeostatic
expansion of na€ıve and memory T cells because of the
accessibility of cytokines (especially IL-7 and IL-15),
which are crucial for the homeostatic proliferation;
(2) depletion of negative cellular elements such as
CD41CD251 T regulatory cells (Tregs); (3) enhanc-
ing the function of antigen presenting cells (APCs);
and (4) the general stimulation of the immune system
caused by the release of tissue injury or inflammatory
‘‘danger signals,’’ such as bacterial translocation and
release of lipopolysaccharide following damage to the
gastrointestinal tract.
The potential for lymphodepletion to enhance the
effectiveness of adoptively transferred T cells has been
clinically studied in both hematologic and solid malig-
nancies. In heavily pretreated patients with refractory
non-Hodgkin lymphoma, rapid lymphocyte recoverywas observed and in some cases significant delayed
lymphocytosis occurred, following infusions of auto-
logous ex vivo cultured lymphocytes in patients treated
with high-dose chemotherapy and autologous CD341
stem cell transplant [20]. Initial reports in melanoma
using tumor-infiltrating lymphocytes (TIL) demon-
strated modest response rates (about 30%), and
responses were often not durable. A substantial in-
crease in the effectiveness of TIL therapy came with
addition of host preconditioning using nonmyeloabla-
tive chemotherapy as reported by Dudley et al. [21].
To induce lymphodepletion, patients received a condi-
tioning regimen consisting of cyclophosphamide
(60 mg/kg for 2 days) and fludarabine (25 mg/m2 for
5 days) before adoptive transfer of TILs. Patients
were subsequently treated with high-dose IL-2. In
this report, up to 50% of patients achieved an objective
clinical response with many of these responses being
quite durable, including completely responding
patients rendered disease free.
More recently, it was shown that increasing the in-
tensity of the conditioning regimen by adding TBI of
200 cGy to 1200 cGy could further increase response
rates [8]. Objective response rates using Response
Evaluation Criteria in Solid Tumors (RECIST)
criteria reached 72% with maximum lymphodeple-
tion, including 32% of patients with complete tumor
regressions. These responses were durable, and only
1 of 16 patients who achieved a complete response
ever recurred at times ongoing from 32 to 84 months.
Responses were seen at all visceral sites, and there was
no relationship between the bulk of disease and the
likelihood of achieving an objective response.Types of Gene Transfer to T Cells
TCR gene therapy
The success of TIL therapy for the treatment of
metastatic melanoma formed a strong foundation for
TCR-engineered T cells. The first step in TCR gene
therapy is to isolate a T cell clone with high affinity
for a defined target antigen. Genes encoding the
TCR can be isolated from patients with rare reactive
high-avidity T cell clones that recognize and lyse
target tumor cells. The TCR a- and b-chains are iden-
tified, isolated, and cloned into either retroviral or len-
tiviral vectors using recombinant DNA techniques.
The genetic transfer of TCR a- and b-chains directed
against specific tumor antigens can create generic
antigen-specific T cells. The first successful transfer
of a melanoma-reactive TCR to human peripheral
blood lymphocytes (PBLs) conferring antitumor
reactivity was reported in 1999, and since then, several
reports demonstrated that transfer of a tumor antigen-
specific TCR into T cells results in an antigen-specific
T cell population [22]. This approach bypasses the
Biol Blood Marrow Transplant 17:S15-S20, 2011 S17Genetic Modification of T Cellsneed to isolate the tumor-specific effector cells from
each patient. TCR-engineered T cells secrete immu-
nostimulatory cytokines, exert antigen-specific cyto-
toxicity upon encounter with antigen-positive tumor
cells, and expand in response to this antigenic stimula-
tion.
The first human clinical trial of TCR gene therapy
was reported in 2006 for the treatment of metastatic
melanoma [23]. In this phase I trial, HLA-A2–
positive metastatic melanoma patients were treated
with retrovirally transduced autologous PBLs express-
ing a TCR against MART-1. Gene transfer efficiency
in this trial was in the range of 21% to 72% as assessed
by the staining for the TCR b-chain, and was distrib-
uted equally between CD4 and CD8 cells. Gene-
modified T cells were detected as long as 1 year after
adoptive cell transfer. FollowingT cell infusion, tumor
regression was observed in 2 out of 17 patients. In
addition to the initial report, a total of 31 patients
were treated in this protocol and 4 patients (13%) ex-
perienced an objective regression of metastatic mela-
noma. Response rate in this first human TCR clinical
trial is less than that of the TIL trials that are reported
to be in the range of 50% to 70%. However, this trial
provided the first proof of principle for the novel
genetic immunotherapy involving TCR-modified
T cells.
In an effort to improve the efficacy of TCR-based
therapy, a high-avidity TCR that recognized the
MART-1: 27-35 epitope was generated. It was antici-
pated that a more highly reactive TCR might yield
more effective tumor response in patients. In this sec-
ond trial, objective cancer regression was observed in
30% of patients [24]. However, patients exhibited de-
struction of normal melanocytes in the skin, eye, and
ear. Local steroid administration was employed to treat
hearing loss and uveitis. This trial revealed that T cells
expressing highly reactive TCRsmediate cancer regres-
sion and also target cognate-antigen–expressing cells
throughout the body. In another trial, a highly reactive
TCR against the human melanocyte differentiation
antigen gp100: 154-162 epitope raised by immunizing
HLA-A0201 transgenic mice was used to treat mela-
noma patients [24]. Cells expressing the murine TCR
in this trial persisted at similar levels as the cells express-
ing the human TCR against MART-1 and mediated
tumor regression. An objective clinical response rate
of 19% was reported in this trial. The transfer of
T cells engineered with TCRs directed against mela-
noma differentiation antigens MART-1 and gp100
resulted in a 13% to 30%objective response rate, which
was still lower than the 50% to 70% rate seen in TIL
therapy.
TCR gene therapy for cancer is now being prac-
ticed in several centers worldwide, and rapid progress
should continue as the approach expands to treat other
malignancies and adapts procedures to simplify bothtechnological and regulatory requirements that have
limited application.
Chimeric antigen receptors (CARs)
Instead of transducing T cells with additional
abTCR, it is possible to transfer chimeric TCRs. These
consist of an antigenbinding exodomain and aTcell sig-
naling endodomain. Most commonly, CARs are gener-
ated by joining the light- and heavy-chain variable
regions of a monoclonal antibody expressed as a sin-
gle-chain Fv (scFv) molecule with the transmembrane
and cytoplasmic signaling endodomains derived from
the CD3 z chain of the native T cell receptor, or from
theFc receptorg chain, using a flexible spacer. Although
CARscan alsobe preparedby combining cellmembrane
receptors/ligands (such as cytokine receptors) with the
same endodomains, such an approach is used more
rarely. CARs therefore usually combine the antigen
specificity of an antibody and the cytotoxic properties
of a T cell in a single fusion molecule.
Because CARs bind to target antigens in an HLA-
unrestrictedmanner, they are resistant tomany tumor-
immune evasion mechanisms, such as downregulation
of HLA class I molecules or failure to process or pres-
ent proteins. First-generation CARs incorporated the
cytoplasmic region (endodomains) from the CD3 z
or the Fc receptor g chains as their signaling domain.
Although these receptors successfully redirected
T cell cytotoxicity, they failed to stimulate T cell pro-
liferation and survival in vivo, likely because of the lack
of appropriate costimulatory signals to T cells follow-
ing engagement of their CAR. Efficacy was therefore
modest in clinical trials in subjects with lymphoma,
ovarian, neuroblastoma, or renal cancer summarized
in Table 1 [25-29].
Second-generation CARs were constructed by
incorporating signaling domains from individual
costimulatory molecules such as CD28, OX40, and
4-1BB within the endodomain, and improved
antigen-specific T cell activation and expansion.
Third-generation CARs include a combination of cos-
timulatory endodomains [30], but there are concerns
that such receptors may either be too easily triggered
by low-avidity ‘‘off-target’’ binding or may produce
too potent an activation signal, producing potentially
lethal consequences from the resulting cytokine
storm. Troublingly, there have already been reports
of 2 fatalities associated with the use of second- and
third-generation CARS targeting CD19 in subjects
with B-CLL and HER2 in solid tumors. Although
these problems were attributed to a combination of
cyclophosphamide/infection and to crossreactivity
with normal tissues expressing HER2, both events
were associated with high cytokine levels [31-33]. An
alternative approach is to express CARs in antigen-
specific T cells, which will then also be activated and
expanded through engagement of their native abTCR
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S18 Biol Blood Marrow Transplant 17:S15-S20, 2011C. Bonini et al.by antigen on professional antigen presenting cells,
with attendant costimulation [34]. For example, sub-
jects receiving EBV-specific CTLs engineered with
a CAR (CAR-CTLs) specific for the disialoganglio-
side antigen GD2a on neuroblastoma cells show lon-
ger in vivo persistence of CAR-CTLs compared with
unselected T cells engineered with the identical
CAR, because the CAR-CTLs encounter (persistent)
EBV antigens [34]. Longer persistence has been asso-
ciated with tumor responses including 3 complete re-
missions (sustained in 2) in 10 patients with advanced
relapsed disease.
Overcoming immune evasion strategies
One of the main challenges to effective adoptive
T cell therapy is the lack of in vivo expansion and
maintenance of ex vivo manipulated, adoptively
transferred T cells because of tumor-induced immune
evasion mechanisms. Gene transfer technologies allow
us to modify T cells and restore their functionality in
a hostile environment. For example, many tumor cells
or their associated stroma produce transforming
growth factor-beta (TGF-b), which favors the devel-
opment of immune tolerance and T cell anergy, induc-
ing T effector cell growth arrest with induction of
Tregs. Bollard and coworkers [35,36] showed that
human and murine antigen-specific T cells could
express a dominant negative (dn) TGF-b receptor fol-
lowing retroviral transduction and become resistant to
the antiproliferative effects of TGF-b retaining their
effector function in vivo. T cells may also be modified
to express cytokine or cytokine receptor genes that
mimic the milieu found during lymphoid regeneration
and restoration of homeostasis, such as interleukin
(IL)-2, IL-7, or IL-15 [15,37,38]. Preliminary clinical
data are encouraging but as yet, we do not know for
certain how safe or effective these transgenic cytokines
and their receptors will be. An alternative strategy is
administer antibodies to receptors on T cells that have
an inhibitory effect on T cell activation such as
CTLA4 (cytotoxic T lymphocyte antigen-4) and PD-1
(programmed death-1).
CytotoxicTcells can also bemade resistant to small
molecule cancer therapeutics, many of which cause
profound immunosuppression. Several possibilities
exist, from the introduction of drug metabolizing en-
zymes to expression of rapalog resistant mTOR.Other
investigators have made T cells that express transgenic
calcineurin molecules resistant to commonly used
posttransplant immunosuppressive drugs such as
cyclosporine or silenced the FK506-binding protein
with a specific small interfering RNA [39,40],
potentially allowing administration of allogeneic
cancer specific T cells to subjects with cancer whose
own immune system is prevented from rejecting the
allogeneic cells by immunosuppressive drugs. The
overall value of this approach remains to be established.
Biol Blood Marrow Transplant 17:S15-S20, 2011 S19Genetic Modification of T CellsSuicide gene strategies
Because transduced T cells have the potential to
last the lifetime of the host and even to expand in num-
ber, any adverse effect attributable to gene transfer or
gene-modified cells may worsen over time. This is
a particular concern when we engineer T cells to
enable them to resist the physiological ‘‘off signals’’
that are exploited by many cancers to subvert
tumor immune recognition and effector function.
The more independent wemake T cells of normal reg-
ulatory signals, the more critical becomes the concern
of quis custodiet ipsos custodes (whowill guard the guards)?
Suicide strategies use a second transgene that ac-
companies the gene of interest, and that allows the
cell to be destroyed on exposure to a specific signal.
The most widely used is the herpes simplex viral
thymidine kinase (Tk) gene, the product of which
will phosphorylate ganciclovir or acyclovir to the ac-
tive moiety, which interferes with DNA synthesis
[41]. The Tk gene has been introduced into allogeneic
T lymphocytes used as donor lymphocyte infusions
following stem cell transplantation. If the infused cells
produce graft-versus-host disease (GVHD) rather
than the desired antiviral and antileukemic activity,
they can be inactivated by administration of the ganci-
clovir prodrug. Tk cells have been infused within
several clinical trials in more than 120 patients after
HLA-identical and haploidentical stem cell trans-
plants. Every case of GVHD occurring after the
infusion of Tk cells was controlled, indicating the
efficacy of the suicide gene/prodrug system in control-
ling alloreactivity. The safety and benefits of this
approach appear substantial and the approach has
now reached phase III clinical trial [42]. Although
apparently effective, the Tk gene may itself be immu-
nogenic, leading to undesired elimination of a trans-
duced cell population [43]. Moreover, gancyclovir is
a useful drug for immunocompromised patients who
develop CMV infections; in these patients, administra-
tion of GCV to treat CMV would produce cell suicide
irrespective of need. Finally, Tk/GCV may have
limited ability to actually kill cell populations, particu-
larly those that are post mitotic. Although in some
clinical conditions, for example, acute GVHD
(aGVHD), the selective elimination of highly pro-
liferating gene-modified lymphocytes might be of
benefit, because it spares resting T cells, potentially
harboring relevant specificities, in other settings, a
suicide gene/prodrug system independent of the cell
cycle would be advantageous. Investigators are
therefore developing alternatives such as inducible
Caspase9 (icasp9). Because icasp9 is a naturally occur-
ring component of the caspase pathway it should be
nonimmunogenic and produce apoptosis even in non-
dividing cells [44]. The molecule can be triggered by
administration of a small molecule dimeriser thatbrings together 2 nonfunctional icasp9 molecules to
form the active enzyme. The approach has begun clin-
ical study in recipients of T cell-depletedHLA-haploi-
dentical donor stem cell transplants and is producing
promising results. iCasp9 transduced cells have good
engraftment and functionality but can be destroyed
within minutes after administration of the dimerizer
drug with resolution of GVHD.CONCLUSIONS
Although the gene transfer strategies described
above are showing clinical promise, they are complex
and challenging tomove forward to later phase testing.
Approaches to simplify manufacture of genetically
modified T cells are currently under evaluation, in-
cluding the use of artificial APCs to provide a rapid
source of antigen [45] and bioreactors in which to pre-
pare these cells in a closed system [46]. Hopefully,
these modifications will allow such therapies to be
broadly implemented and move forward to testing in
multicenter trials.ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to
disclose.REFERENCES
1. Kolb HJ. Graft-versus-leukemia effects of transplantation and
donor lymphocytes. Blood. 2008;112:4371-4383.
2. Leen AM,Myers GD, Sili U, et al. Monoculture-derived T lym-
phocytes specific for multiple viruses expand and produce
clinically relevant effects in immunocompromised individuals.
Nat Med. 2006;12:1160-1166.
3. O’Reilly RJ,Doubrovina E, TrivediD, et al. Adoptive transfer of
antigen-specific T-cells of donor type for immunotherapy of
viral infections following allogeneic hematopoietic cell trans-
plants. Immunol Res. 2007;38:237-250.
4. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy
for early cytomegalovirus infection after allogeneic stem-cell
transplantation with virus-specific T-cell lines. Lancet. 2003;
362:1375-1377.
5. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of
EBV-specific T-cell infusions to prevent or treat EBV-related
lymphoproliferative disease in transplant recipients. Blood.
2010;115:925-935.
6. Warren EH, Fujii N, Akatsuka Y, et al. Therapy of relapsed
leukemia after allogeneic hematopoietic cell transplantation
withT cells specific forminor histocompatibility antigens. Blood.
2010;115:3869-3878.
7. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses
of relapsed lymphoma following genetic modification of tumor-
antigen presenting cells and T-lymphocyte transfer. Blood. 2007;
110:2838-2845.
8. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell
transfer therapy following non-myeloablative but lymphode-
pleting chemotherapy for the treatment of patients with
refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-
2357.
S20 Biol Blood Marrow Transplant 17:S15-S20, 2011C. Bonini et al.9. Zou W. Immunosuppressive networks in the tumour environ-
ment and their therapeutic relevance. Nat Rev Cancer. 2005;5:
263-274.
10. Stewart TJ, Abrams SI. How tumours escape mass destruction.
Oncogene. 2008;27:5894-5903.
11. Ciceri F, Bonini C, Marktel S, et al. Antitumor effects of HSV-
TK-engineered donor lymphocytes after allogeneic stem-cell
transplantation. Blood. 2007;109:4698-4707.
12. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of
effector CD81T cells derived from central memory cells estab-
lishes persistent T cell memory in primates. J Clin Invest. 2008;
118:294-305.
13. Hinrichs CS, Borman ZA, Cassard L, et al. Adoptively trans-
ferred effector cells derived from naive rather than central mem-
ory CD81 T cells mediate superior antitumor immunity. Proc
Natl Acad Sci U S A. 2009;106:17469-17474.
14. Kaneko S, Mastaglio S, Bondanza A, et al. IL-7 and IL-15 allow
the generation of suicide gene-modified alloreactive self-
renewing central memory human T lymphocytes. Blood. 2009;
113:1006-1015.
15. Hoyos V, Savoldo B, Quintarelli C, et al. Engineering CD19-
specific T lymphocytes with interleukin-15 and a suicide gene
to enhance their anti-lymphoma/leukemia effects and safety.
Leukemia. 2010;24:1160-1170.
16. Mills CD, North RJ. Expression of passively transferred immu-
nity against an established tumor depends on generation of cyto-
lytic T cells in recipient. Inhibition by suppressor T cells. J Exp
Med. 1983;157:1448-1460.
17. Wang LX, Shu S, Plautz GE. Host lymphodepletion augments
T cell adoptive immunotherapy through enhanced intratu-
moral proliferation of effector cells. Cancer Res. 2005;65:
9547-9554.
18. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor re-
gression and autoimmunity after reversal of a functionally toler-
ant state of self-reactive CD81 T cells. J Exp Med. 2003;198:
569-580.
19. Muranski P, Boni A, Wrzesinski C, et al. Increased intensity
lymphodepletion and adoptive immunotherapy—how far can
we go? Nat Clin Pract Oncol. 2006;3:668-681.
20. Laport GG, Levine BL, Stadtmauer EA, et al. Adoptive transfer
of costimulated T cells induces lymphocytosis in patients with
relapsed/refractory non-Hodgkin’s lymphoma following
CD3412selected hematopoietic cell transplantation. Blood.
2003;102:2004-2013.
21. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regres-
sion and autoimmunity in patients after clonal repopulation with
antitumor lymphocytes. Science. 2002;298:850-854.
22. Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy:
geneticmodification to redirect effector cell specificity.Cancer J.
2010;16:336-341.
23. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regres-
sion in patients after transfer of genetically engineered lympho-
cytes. Science. 2006;314:126-129.
24. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with
human and mouse T-cell receptors mediates cancer regression
and targets normal tissues expressing cognate antigen. Blood.
2009;114:535-546.
25. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study
on adoptive immunotherapy using gene-modified T cells for
ovarian cancer. Clin Cancer Res. 2006;12:6106-6115.
26. JensenMC, Popplewell L, Cooper LJ, et al. Antitransgene rejec-
tion responses contribute to attenuated persistence of adoptively
transferred CD20/CD19-specific chimeric antigen receptor re-
directed T cells in humans. Biol Blood Marrow Transplant. 2010;
16:1245-1256.
27. Till BG, JensenMC,Wang J, et al. Adoptive immunotherapy for
indolent non-Hodgkin lymphoma and mantle cell lymphoma
using genetically modified autologous CD20-specific T cells.
Blood. 2008;112:2261-2271.
28. Lamers CH, Langeveld SC, Groot-van Ruijven CM, et al.
Gene-modified T cells for adoptive immunotherapy of renalcell cancer maintain transgene-specific immune functions in
vivo. Cancer Immunol Immunother. 2007;56:1875-1883.
29. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chi-
meric antigen receptor re-directed cytolytic T lymphocyte
clones in patients with neuroblastoma. Mol Ther. 2007;15:
825-833.
30. Zhao Y, Wang QJ, Yang S, et al. A herceptin-based chimeric
antigen receptor with modified signaling domains leads to
enhanced survival of transduced T lymphocytes and antitumor
activity. J Immunol. 2009;183:5563-5574.
31. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious
adverse event following the administration of T cells transduced
with a chimeric antigen receptor recognizing ERBB2.Mol Ther.
2010;18:843-851.
32. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment
of chronic lymphocytic leukemia with genetically targeted autol-
ogous T cells: case report of an unforeseen adverse event in
a phase I clinical trial. Mol Ther. 2010;18:666-668.
33. Heslop HE. Safer CARS. Mol Ther. 2010;18:661-662.
34. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells en-
gineered to coexpress tumor-specific receptors: persistence and
antitumor activity in individuals with neuroblastoma. Nat Med.
2008;14:1264-1270.
35. Foster AE, Dotti G, Lu A, et al. Antitumor activity of EBV-
specific T lymphocytes transduced with a dominant negative
TGF-beta receptor. J Immunother. 2008;31:500-505.
36. Bollard CM, Rossig C, CalongeMJ, et al. Adapting a transform-
ing growth factor beta-related tumor protection strategy to en-
hance antitumor immunity. Blood. 2002;99:3179-3187.
37. Vera JF, Hoyos V, Savoldo B, et al. Genetic manipulation of
tumor-specific cytotoxic T lymphocytes to restore responsive-
ness to IL-7. Mol Ther. 2009;17:880-888.
38. Heemskerk B, Liu K, Dudley ME, et al. Adoptive cell therapy
for patients with melanoma, using tumor-infiltrating lympho-
cytes genetically engineered to secrete interleukin-2. Hum
Gene Ther. 2008;19:496-510.
39. Brewin J, Mancao C, Straathof K, et al. Generation of EBV-
specific cytotoxic T-cells that are resistant to calcineurin inhib-
itors for the treatment of post-transplant lymphoproliferative
disease. Blood. 2009;114:4792-4803.
40. De Angelis B, Dotti G, Quintarelli C, et al. Generation of
Epstein-Barr-virus-specific cytotoxic T lymphocytes resistant
to the immunosuppressive drug tacrolimus (FK506). Blood.
2009;114:4784-4791.
41. Bonini C, Bondanza A, Perna SK, et al. The suicide gene therapy
challenge: how to improve a successful gene therapy approach.
Mol Ther. 2007;15:1248-1252.
42. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-
gene-engineered donor lymphocytes after family haploidentical
haemopoietic stem-cell transplantation for leukaemia (the
TK007 trial): a non-randomised phase I-II study. Lancet Oncol.
2009;10:489-500.
43. Traversari C, Marktel S, Magnani Z, et al. The potential immu-
nogenicity of the TK suicide gene does not prevent full clinical
benefit associated with the use of TK-transduced donor lympho-
cytes in HSCT for hematologic malignancies. Blood. 2007;109:
4708-4715.
44. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK.
Inducible caspase 9 suicide gene to improve the safety of allode-
pleted T cells after haploidentical stem cell transplantation. Biol
Blood Marrow Transplant. 2007;13:913-924.
45. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets:
tools, trials and tribulations. Nat Rev Immunol. 2009;9:704-716.
46. Vera JF, Brenner LJ, Gerdemann U, et al. Accelerated produc-
tion of antigen-specific T cells for preclinical and clinical
applications using gas-permeable rapid expansion cultureware
(G-Rex). J Immunother. 2010;33:305-315.
47. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of
B-lineage cells and regression of lymphoma in a patient treated
with autologous T cells genetically-engineered to recognize
CD19. Blood. 2010 [Epub ahead of print].
